alpha-aminopyridine has been researched along with Hematologic Malignancies in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, M; Gao, Y; Gong, Y; Jia, Y; Ling, Y; Liu, X; Yang, C; Yang, Y; Zhou, Y | 1 |
| Cao, HY; Dai, HP; Li, L; Xue, SL | 1 |
| Abdel-Wahab, O; Abramson, D; Arcila, ME; Berger, MF; Ceyhan-Birsoy, O; De Munck, S; Decaux, O; Diamond, EL; Drilon, A; Dunkel, IJ; Durham, BH; Emile, JF; Erickson, C; Geissmann, F; Haroche, J; Hyman, DM; Ki, M; Lacouture, ME; Ladanyi, M; Lopez Rodrigo, E; Lu, SX; Mandelker, D; Mora, J; Pannecoucke, E; Pastore, A; Petrova-Drus, K; Picarsic, J; Rotemberg, V; Saganty, R; Santa-María López, V; Savvides, SN; Solit, DB; Ulaner, GA; Walsh, M; Yabe, M; Yoshimi, A | 1 |
| Albert, DH; Ansell, P; Arellano, M; Garcia-Manero, G; Kadia, T; Kantarjian, H; Khoury, HJ; Knight, EA; McKee, MD; Munasinghe, W; Oliver, B; Qin, Q; Ricker, JL; Roberts-Rapp, L; Tibes, R; Xiong, H | 1 |
1 review(s) available for alpha-aminopyridine and Hematologic Malignancies
| Article | Year |
|---|---|
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
Topics: Aminopyridines; Apoptosis; Benzamides; Cell Line, Tumor; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylases; Humans | 2023 |
1 trial(s) available for alpha-aminopyridine and Hematologic Malignancies
| Article | Year |
|---|---|
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor | 2015 |
2 other study(ies) available for alpha-aminopyridine and Hematologic Malignancies
| Article | Year |
|---|---|
Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Hematologic Neoplasms; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors | 2023 |
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Topics: Adolescent; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Benzothiazoles; Child; Child, Preschool; Exome Sequencing; Female; Genome, Human; Hematologic Neoplasms; Histiocytosis; Humans; Infant; Male; Mutation; Picolinic Acids; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Twins, Monozygotic; Young Adult | 2019 |